| Literature DB >> 28211642 |
João Ribas1,2,3, Yu Shrike Zhang1,2, Patrícia R Pitrez4,5, Jeroen Leijten1,2,6, Mario Miscuglio1,2, Jeroen Rouwkema7, Mehmet Remzi Dokmeci1,2, Xavier Nissan8, Lino Ferreira4,5, Ali Khademhosseini1,2,9,10.
Abstract
Organ-on-a-chip platforms seek to recapitulate the complex microenvironment of human organs using miniaturized microfluidic devices. Besides modeling healthy organs, these devices have been used to model diseases, yielding new insights into pathophysiology. Hutchinson-Gilford progeria syndrome (HGPS) is a premature aging disease showing accelerated vascular aging, leading to the death of patients due to cardiovascular diseases. HGPS targets primarily vascular cells, which reside in mechanically active tissues. Here, a progeria-on-a-chip model is developed and the effects of biomechanical strain are examined in the context of vascular aging and disease. Physiological strain induces a contractile phenotype in primary smooth muscle cells (SMCs), while a pathological strain induces a hypertensive phenotype similar to that of angiotensin II treatment. Interestingly, SMCs derived from human induced pluripotent stem cells of HGPS donors (HGPS iPS-SMCs), but not from healthy donors, show an exacerbated inflammatory response to strain. In particular, increased levels of inflammation markers as well as DNA damage are observed. Pharmacological intervention reverses the strain-induced damage by shifting gene expression profile away from inflammation. The progeria-on-a-chip is a relevant platform to study biomechanics in vascular biology, particularly in the setting of vascular disease and aging, while simultaneously facilitating the discovery of new drugs and/or therapeutic targets.Entities:
Keywords: aging; mechanotransduction; organ-on-a-chip; progeria; vascular disease
Mesh:
Substances:
Year: 2017 PMID: 28211642 PMCID: PMC5545787 DOI: 10.1002/smll.201603737
Source DB: PubMed Journal: Small ISSN: 1613-6810 Impact factor: 13.281